Disease burden of chronic lymphocytic leukaemia within the European Union

European Journal of Haematology

Volumn 81, Issue 4, 2008, Pages 253-258

  Watson, Louise ^a,b   Wyld, Peter ^c   Catovsky, Daniel ^d  

^a Apartment 4 Lyndhurst ^*  (United Kingdom)

^b Louise Watson Consulting Ltd   (United Kingdom)

^c Medical Research   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Burden; CLL; Cost of illness; Epidemiology; European Union; Prevalence

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EUROPEAN UNION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION GROWTH; PREVALENCE; PRIORITY JOURNAL;

EUROPEAN UNION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PREVALENCE;

EID: 51649104731     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01114.x     Document Type: Article

References (24)

1. Cheson BD, Bennett JM, Grever M. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia; revised guidelines for diagnosis and treatment. Blood 1996 87 : 4990 7.
2. Kalil N, Cheson BD. Management of chronic lymphocytic leukaemia. Drugs Aging 2000 16 : 9 27.
3. US National Institutes of Health. SEER Overview Section. Available at http://seer.cancer.gov [accessed on 24 September 2007].
4. Diehl LF, Hynds-Karnell L, Menck HR. The national cancer data base report on age, gender, treatment and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999 86 : 2684 92.
5. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001 86 : 8 12.
6. Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978 EUROCARE working group. Eur J Cancer 1998 34 : 2253 63.
7. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003 14 (Suppl. 5 v61 118.
8. Chiorazzi ND, Rai KR, Ferrarini M. Chronic lymphocytic leukaemia. N Engl J Med 2005 352 : 804 15.
9. Oscier D, Fegan C, Hillman P. Guideline for the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 125 : 294 317.
10. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981 48 : 198 206.
11. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975 46 : 219 34.
12. Catovsky D, Richards S, Matutes E, et al. on behalf of the UK National Cancer Research Institute Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 370 : 230 9.
13. Hallek M. Chronic lymphocytic leukemia (CLL): first line treatment. Hematology Am Soc Hematol Program 2005 285 91.
14. Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease - progression on overall survival. Haematologica 1999 84 : 1094 9.
15. International Agency for Research on Cancer (IARC). GLOBOCAN 2002. Available at http://www-dep.iarc.fr [accessed on 24 September 2007].
16. Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI. Incidence rates of the major leukemia subtypes amongst U.S. Hispanics, Blacks and non-Hispanic Whites. Leuk Lymphoma 2006 47 : 2365 70.
17. ONS. Office of National Statistics (ONS) Cancer Statistics - 2004. Available at http://www.statistics.gov.uk ; last accessed on 24 September 2007.
18. Ghia P, Stamatopolous K, Belessi C, et al. Geographic patterns and pathogenic implications of IGHV gene usage in chronic lymphocytic leukemia - the lesson of the IGHV3-21 gene. Blood 2005 105 : 1678 85.
19. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21 using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006 107 : 2889 94.
20. Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for twenty-five sites in the adult population. Int J Cancer 2002 97 : 72 81.
21. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL. Chronic lymphocytic leukaemia: economic burden and quality of life: literature review. Am J Ther 2005 12 : 460 6.
22. Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R. Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care 2006 15 : 379 85.
23. Kirchstein R. Disease Specific Estimates of Direct and Indirect Costs of Illness and NIH Support. Bethesda, MD, USA : Office of the Director, 2000.
24. Mauro FR, Foa R, Gianarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999 94 : 448 54.